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Introduction 1
Every day we depend on our cells to make the right decision -to divide or not to divide. 2 Proliferation is essential for tissue homeostasis, but when deregulated can both promote cancer and 3 lead to aging. For this reason, the decision to replicate is tightly controlled by a complex network of cell 4 cycle regulatory proteins. In the early 1990s, it was clear that the catalytic activity of cyclin dependent 5 kinases (CDKs) was required to drive cellular division. Less obvious were the signals that regulate CDK 6 activity and how these became altered in neoplastic disease. In an attempt to address this very 7 question, Beach and colleagues made the observation that CDK4 bound a distinct, 16 kilodalton protein 8 in cells transduced with a viral oncogene (1) . Biochemical characterization of this protein, later named 9 p16 INK4a , placed it amongst the INK4-class of cell cycle inhibitors, which bind directly to CDK4 and CDK6, 10 blocking phosphorylation of the retinoblastoma tumor suppressor (RB) and subsequent traversal of the 11 G1/S cell cycle checkpoint ((2, 3); Fig. 1A ). In the presence of various stressors (e.g. oncogenic signaling, 12 DNA damage), p16 INK4a to yield two distinct proteins: p16 INK4a and ARF (p14 ARF in humans, p19 ARF in mice). In addition to CDKN2A, 18 the INK4/ARF locus encodes a third tumor suppressor protein, p15 INK4b , just upstream of the ARF 19 promoter (3). Discovered through homology-based cDNA library screens, p15 INK4b functions analogously 20 to p16 INK4a , directly blocking the interaction of CDK4/6 with D-type cyclins (2, 3) . In contrast to p15 INK4b 21 and p16 INK4a which function to inhibit RB phosphorylation, ARF expression stabilizes and thereby 22 activates another tumor suppressor, p53 (5, 6) . Like the INK family of inhibitors, p53 functions to block 23 inappropriate proliferation and cellular transformation. Through a poorly understood mechanism, likely 24 Page | 6
To maintain tissue homeostasis and prevent cancer, the ability of p16 INK4a to inhibit cellular 1 proliferation must be tightly controlled. In this section, we discuss the role of chromatin, transcriptional 2 co-factors and RNAs in maintaining proper p16 INK4a expression. In addition, we highlight the complexity 3 and redundancy of p16 INK4a regulatory pathways required for proper proliferative control. Chromatin modifications by the polycomb group complexes (PcGs), PRC1 and PRC2, are critical 7 to the homeostatic regulation of INK4/ARF gene expression ( Fig. 2A) . The PRC2 complex is made up of 8 four core components: EZH1/2, EED, SUZ12 and RBAp46/48. EZH1 or 2 serves as the catalytic subunit of 9 PRC2 and functions only in the presence of EED and SUZ12 to compact chromatin through the di-and 10 tri-methylation of histone H3 lysine 27 (H3K27me2/3) (29, 30) . H3K27me3 is recognized by a 11 chromodomain-containing CBX protein family member associated with PRC1. In this manner, PRC1 is 12 recruited to the INK4/ARF locus, where it catalyzes the ubiquitylation of histone H2A lysine 119 13 (H2AK119ub), resulting in further chromatin compaction and gene silencing (31) . Multiple variants of 14 the PRC1 complex have been identified in vivo, each containing homologs of the Drosophila Posterior 15 Sex Comb (Psc; NSPC1/PCGF1, MEL-18/PCGF2, RNF3/PCGF3, BMI1/PCGF4, RNF159/PCGF5, 16 RNF134/PCGF6), Polycomb (Pc; CBX2, CBX4, CBX6, CBX7, CBX8), Sex Combs Extra (RING1, RING2) and 17 Polyhomeotic proteins (Ph; HPH1, HPH2, HPH3) (32) . PRC1 complexes contain a single Psc and Pc 18 homolog, yet Maertens et al. observed binding of MEL-18, BMI-1, CBX7 and CBX8 to the repressed 19 INK4/ARF locus (32) . Further investigation revealed that multiple PRC1 variants bind to the p16 INK4a 20 promoter, working in a concerted manner to control gene expression (32) . It remains to be determined 21 whether recently reported non-canonical PRC1 complexes that lack a Pc homolog, contain RYBP/YAF2, 22 and are recruited to chromatin independent of H3K27me3 (33) can also function to regulate INK4/ARF 23 gene expression. However, regardless of their composition, PRC1 and 2 complexes clearly bind 24 Page | 7 throughout the INK4/ARF locus, and repress p16 INK4a expression in young, unstressed cells (31) . 1
Maintenance of this repression may be partially dependent on the ubiquitin-specific protease, USP11, 2 which was also shown by Maertens et al. to bind and stabilize the PRC1 complex (34) . In their work, 3 depletion of USP11 caused polycomb complexes to dissociate from the INK4/ARF locus leading to 4 subsequent de-repression of p16 INK4a . 5
The importance of PRC1 and PRC2 for proper p16 INK4a regulation may be best exemplified by the 6 phenotypes of polycomb knockout mice. Deletion of the PRC1 component, Bmi1, results in homeotic 7 skeletal transformations, lymphoid and neurological defects (35). Many of these phenotypes are 8 attributable to the deregulation of homeobox gene expression, however, the lymphoid and neurological 9 defects observed in Bmi1 knockout mice can be almost completely rescued by INK4/ARF deletion (36) . 10
Here, INK4/ARF loss reverses the self-renewal defects of Bmi1-null hematopoietic and neuronal 11 progenitors (37, 38) . Together, these data show that PRC1 regulation of p16 INK4a expression is required 12 for proper development, stem cell maintenance and homeostasis. In contrast to PRC1-null animals 13 which survive gestation, deletion of the PRC2 members, Ezh2 or Suz12, is embryonic lethal (39, 40) . For 14 this reason, conditional knockout alleles are required to assess the biological functions of PRC2. Using 15 such alleles to delete Ezh2 in the brain, pancreas and embryonic skin, phenotypic outcomes have been 16 observed. Specifically, loss of Ezh2 in murine pancreatic islets causes a diabetic phenotype associated 17 with increased β-cell expression of both p16 INK4a and ARF (41) . In contrast, Ezh2 deletion in the brain 18 and skin resulted in only mild differentiation defects (42, 43) . The recent observation that EZH1 is 19 expressed in many adult tissues and also catalyzes histone H3 methylation led to the hypothesis that 20 EZH1 may compensate for EZH2 loss in some settings. Indeed, deletion of both Ezh1 and 2 caused 21 severe defects in murine skin morphogenesis associated with a >70-fold increase in p16 INK4a /ARF 22 expression (43). 23
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Supporting a role for EZH2 in maintaining proliferative homeostasis, human germline mutations 1 in EZH2 give rise to Weaver syndrome, a congenital disorder characterized by uncontrolled and rapid 2 growth (44) . While this phenotype could be attributed to p16 INK4a silencing , few reports have attempted  3 to functionally characterize the EZH2 missense mutations commonly associated with Weaver syndrome 4 (44) . Instead, work has focused on recurring point mutations reported in B-cell lymphoma. These 5 mutations localize to tyrosine 641 of the EZH2 SET domain, resulting in the production of a neomorphic 6 protein with enhanced H3K27 di-and tri-methylation activity (45) . Of importance, not all cancer-7 associated EZH2 mutants are gain-of-function alleles. In myleloid neoplasms, missense, nonsense and 8 frameshift mutations in EZH2 have been described which lack a catalytic SET domain (46) . In addition, 9 the expression of wildtype EZH2 has been reported to cause p16 INK4a silencing in SNF5-deficient 10 malignant rhabdoid tumors (MRTs) (47) . Deletion or pharmaceutical inhibition of EZH2 activity in cells 11 from these tumors increases p16 INK4a expression, resulting in cell cycle inhibition (47, 48) . Together, 12 these observations suggest that EZH2 activity must be tightly controlled in order to maintain 13 proliferative homeostasis and proper p16 INK4a regulation. 14
15
Recruiting Polycomb to CDKN2A 16 In Drosophila melanogaster, polycomb group proteins are recruited to defined DNA binding sites 17 termed, Polycomb repressive elements (PREs) (Reviewed in: (49) H3K27me3 to promote INK4/ARF gene silencing ( Fig. 2A and (10)). Subsequently, ANRIL binding to 1 SUZ12, a component of the PRC2 complex, was reported to promote silencing of p15 INK4b , but not 2 p16 INK4a (50) . Together with these data, a report showing that MOV10, a putative RNA helicase and PRC1 3 binding partner, is required for p16 INK4a repression, supports a role for ANRIL in polycomb recruitment to 4 the INK4/ARF locus (51) . Whether MOV10 binds ANRIL to facilitate PRC1 interaction with the INK4/ARF 5 locus has yet to be determined. However, together these data make a strong case for the role of ANRIL 6 in epigenetic silencing of p16 INK4a . 7
ANRIL-independent mechanisms are also suggested to recruit PcG complexes to the p16 INK4a facilitate PRC2 recruitment to the p16 INK4a promoter ( Fig. 2A and (52)). While the mechanism has yet to 10 be defined, six other homeobox-containing proteins (HOXA9, DLX3, HOXB13, HOXC13, HOXD3 and 11 HOXD8) were similarly reported to participate in p16 INK4a silencing (52) . Given the role of HOX genes in 12 developmental patterning, it is interesting to speculate that proteins like HLX1 and HOXA9 initiate 13 tissue-specific silencing of p16 INK4a . Like HOX proteins, both TWIST1, a basic helix-loop-helix (bHLH) 14 transcription factor, and KDM2B, a histone demethylase, may also facilitate polycomb-mediated 15 silencing of the INK4/ARF locus. Ectopic expression of TWIST1 and KDM2B can cause cellular levels of 16 EZH2 to rise, resulting in an increase in PRC2 activity (53) . KDM2B was further reported to function in 17 demethylating H3K36me2/3, a common marker for DNA polymerase II transcription (53) . Furthermore, 18 TWIST1 appears to increase BMI1 expression (55) , and subsequent recruitment of BMI1 to the p16 INK4a 19 promoter has been linked to interactions with phosphorylated RB (pRB) and zinc finger domain-20 containing protein 277 (ZFP277) (54, 55) . In particular, the link between pRB and p16 INK4a silencing is 21 intriguing as it suggests the presence of a feedback loop wherein cells entering S-phase repress p16 INK4a the G1 to S-phase transition releases E2F1 to transactivate EZH2 and EED (56) . Later, these data were 11 confirmed by an independent group who showed that p53 activation represses EZH2 expression through 12 RB-mediated inhibition of E2F1 activity (57) . While these results explain how the activity of PRC2 might 13 be curbed in the presence of stress, they do not explain how epigenetic silencing of the p16 INK4a 14 promoter is reversed. One mechanism of removing repressive histone marks is via the activity of 15 histone demethylases. In response to oncogenic stressors, levels of the H3K27me3 demethylase, Jmjd3, 16 increase, removing repressive histone marks from the p16 INK4a promoter ( Fig. 2B ; (58, 59) ). Following 17 histone demethylation, the Yokoyama lab showed that Jun dimerization protein 2 (JDP2) may help 18 maintain p16 INK4a in an active state by binding and sequestering H3K27 away from the actions of PRC2 19 (60) . These findings suggest that the activity of JDP2 and JMJD3 establishes a permissive state for 20 The presence of a permissive chromatin state alone is insufficient for p16 INK4a expression. 6
Binding of activation factors and the subsequent recruitment of RNA polymerase is required to initiate 7 p16 INK4a transcription ( Fig. 3 ). Similar to the interplay between PRC2 and JMJD3, transcriptional 8 regulation of the p16 INK4a promoter is tightly controlled by antagonistic pathways. Serving as a classic 9 example, induction of p16 INK4a by the E-box binding transcription factors E-26 transformation-specific 1 10 (ETS1), E-26 transformation-specific 2 (ETS2) and E47, is directly opposed by Inhibitor of DNA Binding 1 11 (ID1) (67) . In response to oncogenic and senescent signaling, ETS1, ETS2 and/or E47 bind to E-box 12 motifs (CANNTG) within the p16 INK4a promoter to stimulate gene expression (67, 68) . This action is 13 directly antagonized by ID1 which prevents interaction of ETS1, ETS2 and E47 with the p16 INK4a promoter 14 (67, 68) . As such, it is not surprising that Id1 null MEFs undergo premature senescence in culture (69), 15
and that age-related increases in p16 INK4a expression correlate directly with ets-1 levels in mice and rats 16 (70) . 17
Similar to ID1, TWIST1 is reported to oppose transcriptional activation of p16 INK4a . The 18 relationship between ID1 and TWIST1 was initially suggested in studies examining the progression of 19 benign human nevi to melanoma. In general, nevi are non-proliferative and express elevated levels of 20 p16 INK4a ; yet, upon progression to melanoma these lesions frequently silence p16 INK4a (71) . Analysis of 21 TWIST1 and p16 INK4a expression in nevi and melanomas revealed an inverse correlation between these 22 two proteins, putting forth the hypothesis that they function in antagonistic pathways (72) . Preliminary 23 work suggested that this antagonism might be mediated through direct interaction of TWIST1 with ETS2 24 Page | 13 (72) , however, in a recent publication by Cakouros et al., TWIST1 was reported to inhibit p16 INK4a 1 transcription by decreasing E47 expression (73) . Clearly, further work is required to fully understand the 2 physiological relationship between p16 INK4a and TWIST1. In addition, it will be of interest to assess the 3 potential role of p16 INK4a in classical TWIST1 pathways including epithelial to mesenchymal transition, 4 stem cell maintenance and tumor metastasis. 5
In line with the relationship between TWIST, ID1 and E-box binding transcription factors, 6 antagonistic interplay has also been described between members of the Activator Protein-1 (AP-1) and can lead to cancer (72, 73, (76) (77) (78) . 13
The HOX family of proteins could also be viewed as antagonistic p16 INK4a regulators. Above, we 14 discussed the potential role of HLX1, HOXA9, DLX3, HOXB13, HOXC13, HOXD3 and HOXD8 in polycomb-15 mediated repression of the INK4/ARF locus. In contrast, the HOX proteins, VENTX, MEOX1 and MEOX2 16 have each been reported to bind the p16 INK4a promoter and activate gene transcription (79) (80) (81) . This 17 proposed interplay between HOX genes and p16 INK4a regulation is suggestive of a role for CDK4/6 18 inhibition in embryonic development. In spite of this, developmental defects are not observed in 19 p16 INK4a knockout mice or melanoma-prone kindreds harboring germline p16 INK4a deficiencies (25, 82) . 20
Whether compensatory mechanisms are required to combat the functional loss of p16 INK4a during 21 development is still to be determined. 22
23

Role of Acetyltransferases and Deacetylases in p16 INK4a Regulation 24
Histone acetylation facilitates chromatin decondensation and subsequent gene transactivation. 1
As such, transcriptional coactivators often harbor or recruit histone acetyltransferase (HAT) activity to 2 target gene promoters. In a pair of recent publications, Wang et al. describe how the transcription 3 factors, SP1 and HMG box-containing protein 1 (HBP1), recruit p300, a well-known HAT, to the p16 INK4a 4 promoter (83, 84) . In their studies, acetylation of local chromatin as well as HBP1, promoted 5 decondensation of the p16 INK4a promoter and subsequent gene transactivation. However, numerous 6 targets of p300 acetylation have been identified to date, including B-MYB, a putative repressor of 7 p16 INK4a transcription (83, 85, 86) . Therefore, the p300-p16 INK4a relationship is likely complex and may be 8 dependent upon the available pool of transcriptional co-factors within a given cell type. 9
HAT activity is opposed by histone deacetylases (HDACs) which promote transcriptional 10 silencing. In human cell lines, HDACs 1-4 have all been reported to bind and repress transcription from 11 the p16 INK4a promoter (52, (87) (88) (89) . Most of these interactions have been linked to bridging transcription 12 factors such as Lymphoid Specific Helicase (LSH), HLX1 and ZBP-89 (87, 89) ; albeit one report suggested 13 that HDAC2 may directly bind the p16 INK4a promoter (88) . While loss of Hdac1, 2, 3 or 4 causes 14 developmental abnormalities and lethality in mice, none of these phenotypes have been attributed to 15 defects in p16 INK4a regulation (90) . 16 17
Age-related Signaling Pathways Influence p16 INK4a Expression 18
The observation that p16 INK4a levels are high in senescent cells has prompted several 19 investigations into the connection between pro-senescent signaling and p16 INK4a regulation. For 20 example, age-related metabolic pathologies have long been associated with activation of the 21 peroxisome proliferator-activated receptors (PPARs). It is now known that these nuclear receptors 22
directly bind and activate the p16 INK4a promoter leading to subsequent cell cycle arrest (91, 92) . 23 Similarly, alterations in TGF-β signaling have been linked to a variety of age-related diseases including 24 cancer, osteoarthritis, cardiovascular disease and Alzheimer's (93) . Work by the Conboy lab has 1 demonstrated that elevated TGF-β signaling reduces the capacity of muscle stem cells to regenerate 2 (94) . Here, phospho-SMAD3 has been shown to directly bind the p16 INK4a promoter, stimulating gene 3 transcription and cell cycle arrest (95) . Due to crosstalk between the TGF-β and β-CATENIN/WNT 4 signaling pathways, it is not surprising that aberrant WNT signaling is also associated with age-related 5 disease (95) . β-CATENIN can directly bind and activate the p16 INK4a promoter in both human and murine 6 cells (96) (97) (98) , and recent evidence links the induction of p16 INK4a by reactive oxygen species (ROS) to β-7 CATENIN/WNT signaling (99) . Together these findings suggest a strong association between age-8 promoting, 'gerontogenic' signals and p16 INK4a expression. The let-7 family of microRNAs has also been implicated in p16 INK4a regulation, proliferative 17 control and stem cell aging. The Morrison group first reported that murine let-7b expression increased 18 with age in neuronal stem cells (108) . Although let-7b did not bind p16 INK4a mRNA directly, 19 overexpression of let-7b reduced the expression of High-Mobility Group AT-Hook 2 (HMGA2), causing 20 p16 INK4a levels to increase (108) . In addition to hmga2, a growing number of RNAs involved in growth 21 and proliferative control have been identified as let-7b targets, and therefore, it is not surprising that 22
the levels of most let-7 family members decrease during tumor progression (109) . 23
In addition to miRNAs, RNA binding proteins can also regulate p16 INK4a translation. Interaction 1 of the Hu RNA binding protein, HuR, with the p16 INK4a 3'UTR have been reported to destabilize the 2 transcript in an miRNA-independent fashion (110) . Work by Zhang et al. suggests that this action is 3 opposed by the tRNA methyltransferase, NSUN2, which methylates the 3'UTR of p16 INK4a to prevent HuR 4 binding and subsequent mRNA degradation (111) . In this way, interplay between HuR and NSUN2 may 5 tightly control p16 INK4a translation. For example, in the presence of oxidative stress, NSUN2 levels 6 appear to increase, tipping the balance towards mRNA stability, p16 INK4a expression and subsequent cell 7 cycle arrest (111) . neck squamous cell carcinoma (HNSC; 63%), lung squamous cell carcinoma (LUSC; 58%) and cutaneous 1 melanoma (SKCM; 58%) ( Fig. 4A ). Examination of individual tumor profiles revealed infrequent overlap 2 between CDKN2A and RB1 deletion, implying that these are often mutually exclusive tumorigenic events 3 (Fig. 4B) . In support of these data, an inverse correlation between p16 INK4a and RB inactivation was 4 previously described in lung cancer cell lines (119) and human tumors (120) . In contrast to RB, we 5 frequently noted alterations within other components of the p16 INK4a tumor suppressor pathway (i.e. 6
Cyclin amplification) in CDKN2A mutant tumors from the TCGA dataset (Fig. 4B ). However, in cases 7
where the p16 INK4a tumor suppressor pathway appeared genetically intact, high levels of RB1 or CDKN2A In most tumor types, p16 INK4a inactivation occurs early in tumorigenesis. For example, 18 pancreatic intraepithelial neoplasias frequently inactivate p16 INK4a upon progression to invasive disease 19 (122) . Pressure to silence p16 INK4a presumably stems from oncogenic engagement of the RB tumor 20 suppressor pathway. Therefore, tumors with early defects in RB signaling continue to express p16 INK4a Unfortunately, there is a paucity of studies that comprehensively examine the status of the RB pathway 7 in multiple human tumor types. Therefore, the critical role of this p16 INK4a -induced checkpoint may be 8
underestimated. 9
Limited analyses of the RB pathway in human tumors have revealed that p16 INK4a expression can 10 be predictive of both tumor subtype and therapeutic response. Elevated p16 INK4a levels discern small 11 cell lung cancer from lung adenocarcinoma (119, 125) and characterize the basal-like breast cancer 12 subtype (126) . Given that tumor subtypes often show distinct therapeutic response profiles, it is not 13 surprising that p16 INK4a expression can predict therapeutic efficacy. For example, elevated p16 INK4a levels 14 predict a higher initial response to radiation therapy in prostatic adenocarcinoma (127) . However, these 15 same p16 INK4a positive tumors are the most likely to fail androgen-deprivation therapy (128 While a myriad of signals are linked to p16 INK4a regulation, most of these are triggered by 1 intrinsic, cell-autonomous events. Employing a recently developed luciferase reporter mouse, p16 LUC , 2
we have observed a second, cell-non-autonomous mechanism of p16 INK4a activation (130) . The p16 LUC 3 allele expresses firefly luciferase from the endogenous p16 INK4a promoter, allowing investigators to 4 dynamically track p16 INK4a transcription in live animals. When the p16 LUC allele was crossed with 5 genetically engineered mouse models (GEMMs) of human cancer, a luminescent signal appeared only in 6 the location of future tumor formation (130) . These luminescent foci were visible weeks before tumors 7 could be visualized or palpated, providing a significant detection advantage over traditional monitoring 8 methods. This incredible sensitivity, along with the observation that tumors maintained luciferase 9 activity during progression, led to the hypothesis that p16 INK4a transcription is activated in the 10 surrounding tumor stroma. Indeed, this was the case as syngeneic transplantation of six p16 LUC -negative 11 tumor cell lines harboring a wide variety of oncogenic drivers caused stromal induction of p16 LUC (Fig.  12 5A and (130)). Although the specific stromal cell types responsible for this observation have yet to be 13 identified, bone marrow transplantation studies suggest that the p16 LUC signal originates in part from 14 bone marrow-derived cells. Therefore, it appears that alterations in the milieu surrounding a growing 15 neoplasm can promote the expression of p16 INK4a in a cell-non-autonomous fashion (Fig. 5B ). 16
Mounting evidence supports a role for stromal p16 INK4a expression in tumor initiation and 17 progression. Fibroblasts ectopically expressing p16 INK4a have altered cellular metabolism and over-18 produce high-energy mitochondrial fuels such as L-lactate (131) . In xenograft studies, co-injection of 19 these fibroblasts with MDA-MB-231 breast cancer cells increased tumor size 2 fold, suggesting that 20 altered stromal metabolism caused by p16 INK4a expression promotes tumor growth (131) . In support of 21 this observation, elevated p16 INK4a levels in the stroma of human mammary ductal carcinoma in situ 22
(DCIS) lesions are predictive of disease recurrence independent of other histopathological markers such 23 as ER positivity (132) . It remains to be determined whether the promotion of tumorigenesis by p16 INK4a positive stromal cells is solely a reflection of altered local metabolism. Studies from the p16 LUC mouse 1 model suggest that p16 INK4a induction in tumor infiltrating immune cells may also promote cancer 2 progression by dampening the anti-tumor response. Regardless of the mechanism, these data make it 3 clear that p16 INK4a expression in the tumor stroma should not be ignored. Pharmaceutical efforts to mimic the function of p16 INK4a arose after the anti-tumor effects of 7 flavopiridol were linked to CDK inhibition (Reviewed in: (133) ). Flavopiridol (alvocidib) was originally 8 touted as an inhibitor of epidermal growth factor receptor (EGFR), but later shown to inhibit the growth 9 of a wide range of cancer cells at an IC 50 much lower than that required to block EGFR activation. Broad 10 inhibition of cyclin dependent kinases (CDKs), including CDK4 (IC 50 <120nM), was later identified as the 11 mechanism of flavopiridol action (134) to inhibition of CDK9, not CDK4/6 (137) . Moreover, the observation that p16 INK4a may contribute to 7 CDK4/6-independent cell cycle regulation (i.e. through CDK inhibitor reshuffling) suggests that 8 pharmaceutical CDK4/6 inhibitors may not fully recapitulate the potency of p16 INK4a . While adverse 9 effects associated with CDK4/6-selective inhibitors are mild (i.e. limited bone marrow suppression) 10 (136) , concerns about the long-term efficacy of such therapeutics is rising. In particular, mechanisms to 11 bypass the requirement for CDK4/6 are already known including: RB loss and increased CDK2 activity. 12
How quickly tumors will exploit these pathways to subvert therapeutic treatment is unknown. Initial 13 trials of PD-0332991 in mantle cell lymphomas speak to this concern. While 89% of study participants 14 showed reduced phospho-RB staining at 3 weeks, only 18% of tumors responded to therapy, suggesting 15 that resistance was rapidly acquired (138) . In addition to concerns about resistance, the role of p16 INK4a 16 expression in the tumor stroma remains undefined and inhibition of the local immune response or 17 altered cellular metabolism may function to promote growth and metastasis. In fact, fibroblasts 18 exposed to PD-0332991 adapt a tumor promoting, metabolic phenotype similar to that of fibroblasts 19 overexpressing p16 INK4a (131) . Therefore, therapeutic mimetics could have similar, detrimental 20 consequences on the tumor microenvironment. A final concern is the long-term effects of CDK4/6 21 inhibition on cellular senescence. Prolonged expression of p16 INK4a promotes senescence and decreases 22 regenerative capacity (See below). In a similar manner, CKD4/6 inhibitors may influence tissue aging. thus unlikely altered by CDK4/6 inhibitors. It may be that stress and/or mitogenic signaling, which often 1 accompany p16 INK4a induction in vitro, is required to elicit senescence, and therefore the effects of 2 CDK4/6 inhibition on aging will be minimal. As more than half of all cancers are diagnosed in people 65 3 and older, determining whether CDK4/6 therapeutics exacerbate age-related disease will be of 4 significant interest. As noted first by Sherr and colleagues (139) , p16 INK4a levels increase with aging. In fact, detailed 12 quantification has demonstrated a direct increase in p16 INK4a expression with chronological age in all 13 mammalian species tested to date (140) . Such increases in p16 INK4a are exponential, rising ~16 fold 14 during the average human lifespan and making p16 INK4a one of the most robust aging biomarkers 15 characterized to date (141) . The induction of senescence and p16 INK4a expression is traditionally 16 associated with a wide variety of intrinsic cellular stressors including: DNA damage, telomere erosion, 17 reactive oxygen species, and stalled replication forks (Reviewed in: (142) ). However, use of the p16 LUC 18 reporter mouse has provided evidence that undefined, extrinsic signals can also trigger p16 INK4a 19 transcription in a cell non-autonomous fashion (130) . Using this same reporter to compare the 20 dynamics of p16 INK4a expression in mice with that observed in humans showed a direct correlation 21 between the rate of p16 INK4a accumulation and lifespan (130) . Furthermore, data from progeroid and 22
calorically restricted rodents suggest that p16 INK4a serves as a marker of biological rather than 23 chronological aging (70, 143, 144 are associated with elevated p16 INK4a expression in the human population (141, 145) . Moreover, skin 1 biopsies from long-lived nonagenarian cohorts have fewer p16 INK4a positive cells than their age-matched 2 partners (146) . Clinically, use of p16 INK4a as a marker of biological aging could provide quantitative 3 measures of patient fitness including immune function and chemotherapeutic tolerance (145, 147) . 4
Assessment of p16 INK4a levels prior to organ transplantation may also aid in the identification of 5 biologically 'younger' donor tissues with increased potential for success (148) (149) (150) . Several lines of evidence suggest that p16 INK4a is not only a biomarker of aging, but also causes 9 aging in many cell types. Using p16 INK4a transgenic and knockout mice, the cell-autonomous role of 10 p16 INK4a in aging has been investigated. In murine hematopoietic stem cells, T-cells, pancreatic β-cells 11 and neural progenitors of the subventricular zone, age-related p16 INK4a expression causes a decline in 12 regenerative capacity (151) (152) (153) (154) . A caveat to these initial studies was the use of germline knockout 13 mice; however strategies employing conditional p16 INK4a loss or siRNAs have since confirmed these 14 findings in T-cells and pancreatic β-cells (154, 155) . Supporting the idea that tissues expressing less 15 p16 INK4a are more biologically fit, kidney transplant success is higher in p16 INK4a -low donor organs (148-16 150) . These data put forth the hypothesis that p16 INK4a expression drives cellular senescence, resulting 17 in decreased regenerative potential. As a proof of principal, work from the Van Deursen lab showed 18 that deletion of p16 INK4a -expressing cells from a BubR1 deficient, progeroid mouse model reduced many 19 aging phenotypes (e.g. sarcopenia, cataracts, loss of adiposity) (144) . Further work by this group 20 showed that both muscle and adipocyte progenitors from these mice express high levels of p16 INK4a , 21 suggesting that even the deletion of senescent stem cells can promote improved regenerative capacity 22 (156) . Unfortunately, these animals did not live longer, owing to the development of cardiac 23 pathologies, and a similar experiment has yet to be reported in wild type mice (144) . One explanation 24 for why these animals were not long-lived is that the gerontogenic effects of p16 INK4a expression are 1 tissue-specific. Indeed, p16 INK4a levels do not seem to influence the regenerative capacity of murine 2 melanocyte stem cells or neuronal progenitors of the dentate gyrus (unpublished observation and (153, 3 157) ). Other mechanisms of curbing age-related p16 INK4a induction have been reported in mice. For 4 example, activation of platelet-derived growth factor receptor (PDGFR) signaling in elderly murine 5 pancreatic β-cells increased the regenerative capacity of these cells via repression of p16 INK4a expression 6 (158) . Likewise, administration of fibroblast growth factor 7 (FGF7) reduced p16 INK4a levels and 7 increased the number of early T-cell progenitors in 15-18 month-old mice, thereby partially rescuing the 8 known decline in thymopoiesis with age (159) . Apart from these studies, analyses of p16 INK4a -mediated 9 regenerative decline are limited to a small number of tissues; therefore the potential outcome of 10 Senescence is typically viewed as a response to detrimental, intrinsic cellular events; however, 16 recent evidence suggests that extrinsic signals also contribute to tissue aging. Above, we discussed the 17 potential for neoplastic transformation to initiate cell non-autonomous p16 INK4a expression. Although 18 the extracellular mediators of stromal p16 INK4a induction are undefined, several signaling pathways have 19 been linked to the expression of p16 INK4a in aging tissues. In muscle satellite cells, age-associated 20 increases in local TGF-β production activate SMAD3, which in turn binds to the p16 INK4a promoter to 21 initiate gene transcription (94) . Notch signaling antagonizes TGF-β, and in doing so can alleviate age-22 related declines in satellite cell function (94) . Similar to TGF-β signaling, changes in thymic and bone 23 marrow structure are reported to promote aging in local progenitor cell populations (142) . Together, 24 these findings put forth the model of "niche aging" wherein stromal changes influence the regenerative 1 capacity of local progenitors. However, parsing the role of the senescent cell versus the niche in aging 2 biology becomes somewhat of a chicken and egg question. After all, senescent cells themselves secrete 3 a large number of pro-inflammatory cytokines associated with age-related disease (Reviewed in: (160) ). 4
Future studies aimed at identifying cell non-autonomous p16 INK4a activation signals are clearly needed to 5 better understand the induction of senescence during physiological aging. reprogramming is effective, silencing of INK4/ARF gene transcription is observed concomitant with the 12 induction of molecular markers indicative of stem cell phenotypes (61) . Therefore, it is not surprising 13 that iPS production efficiency is increased by cellular immortalization (162) , or shRNA knockdown of 14 INK4/ARF genes (61, 161) . Currently, efficient generation of iPS from older patients represents a major 15 hurdle for regenerative medicine. Therefore, novel reprogramming approaches aimed at curbing the 16 senescent phenotype, may improve iPS technology for the future (163 frailty, cataracts and late onset Alzheimer's disease ( Fig. 1B and (164) ). In many cases, expression of 23 associated diseases (164) . Several mechanistic models have been suggested to explain how SNPs, some 1 of which are more than 100 kb from the gene promoter, influence p16 INK4a expression. One model 2 proposes that the activity of distal enhancer elements is modified by SNP genotype (165) . Another 3 provides evidence that ANRIL expression and splicing is directly influenced by 9p21 SNPs (166) . We 4 believe that these models are not mutually exclusive. 5
While mechanisms by which 9p21.3 SNPs influence p16 NK4a transcription have been proposed, 6 the link between p16 INK4a expression and age-related diseases is not always apparent. For example, 7 atherosclerosis is frequently associated with lipid metabolism, yet 9p21.3 SNPs have emerged as robust 8
indicators of atherosclerotic risk in some of the most widely replicated GWASs conducted to date (167). 9
Evidence from animal models suggests that 9p21.3 SNPs may reduce INK4/ARF gene transcription, 10 leading to altered cellular proliferation and apoptosis which exacerbate disease progression (168) (169) (170) (140) , suggesting that the tumor suppressor 10 function of p16 INK4a is somehow more critical than the other INK4/ARF family members. As such, the 11 therapeutic restoration of p16 INK4a activity appears to be a promising avenue for anti-neoplastic 12 development. Ironically, while drug development teams in the field of oncology work fervidly to move 13 CKD4/6 inhibitors into the clinic; aging biologists aim to block the accumulation of p16 INK4a -positive cells. 14 Oddly, the key to longevity likely lies in the hands of both groups, as a careful balance of p16 INK4a 15 expression is required to stave off cancer and prevent aging. 
